Drug
Bilastine
Bilastine: highest development phase Post-Market, developed by Menarini. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Menarini
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bilastine 20mg NCT02761252 | Post-Market | Seasonal Allergic Rhinoconjunctivitis |
Latest
No recent events.
Follow Bilastine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.